[Androgen deprivation therapy for prostate cancer and osteoporotic risk].

Cortet, B; Lartigau, E; Caty, A; Moulinier, F; Staerman, F; Villamizar-Vesga, J; Villers, A

[Androgen deprivation therapy for prostate cancer and osteoporotic risk]. / Suppression androgénique dans le cancer de la prostate et risque ostéoporotique.

Cortet, B; Lartigau, E; Caty, A; Moulinier, F; Staerman, F; Villamizar-Vesga, J; Villers, A.

Affiliation

Cortet B; Service de Rhumatologie, Centre Hospitalier Universitaire, 59000 Lille, France. bernard.cortet@chru-lille.fr

Prog Urol ; 22 Suppl 2: S31-8, 2012 Sep.

Article in Fr | MEDLINE | ID: mdl-23098788

Subject(s)

Androgen Antagonists/adverse effects; Osteoporosis/chemically induced; Osteoporosis/epidemiology; Prostatic Neoplasms/drug therapy; Androgen Antagonists/therapeutic use; Humans; Male; Osteoporotic Fractures/chemically induced; Osteoporotic Fractures/epidemiology; Risk Assessment; Surveys and Questionnaires

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Osteoporosis / Prostatic Neoplasms / Androgen Antagonists Type of study: Etiology_studies / Guideline / Qualitative_research / Risk_factors_studies Limits: Humans / Male Language: Fr Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google